You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業-B(09939.HK)與邁百瑞訂戰略合作 開發生物大分子藥物
阿思達克 09-30 17:49
開拓藥業-B(09939.HK)宣佈,公司與邁百瑞國際生物醫藥簽署戰略合作協議,雙方就生物大分子藥物的研發與生產展開全方位合作。雙方合作的第一個項目GT90008(PD-L1/TGF-β雙抗)的CMC工作將正式啟動。通過此次強強聯合,將加速開拓藥業在生物大分子藥物領域的研發進程,為全球病患提供更多更好的解決方案。

開拓藥業創始人、董事長兼首席執行官童友之稱,開拓藥業正在積極拓展生物藥領域的戰略布局,GT90008項目是公司的第一個雙抗項目,相信邁百瑞公司「一站式」CDMO服務能力能夠高質量的推動GT90008項目的研發進程。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account